Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.us/expertise/influenza/pandemic-response-solutions

Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news

Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine

https://www.seqirus.us/news/seqirus-presents-new-late-breaking-data-at-eswi-2020

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-presents-first-of-its-kind-study-on-cell-based-quadrivalent-influenza-vaccine

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

https://www.seqirus.us/news/seqirus-announces-major-advances-in-pandemic-preparedness

Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

https://www.seqirus.us/news/seqirus-presents-real-world-data-for-cell-based-quadrivalent

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response

https://www.seqirus.us/news/new-clinical-data-reinforces-the-ability-of-mf59-adjuvanted-seasonal-and-pandemic-influenza-vaccines